GENECAST begins clinical research on early diagnosis of lung cancer with Samsung Medical Center
June 14, 2021 05:59 ET
|
GENECAST
Will it be possible to administer EGFR inhibitors to patients with early-stage non-small cell lung cancer (NSCLC)?The real possibility of the commercial use of liquid biopsies for patients with stage...
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Correction: Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 06, 2020 02:34 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
November 02, 2020 10:17 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade The Non-Small Cell Lung Cancer Pipeline...
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
June 19, 2020 00:27 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
June 09, 2020 08:00 ET
|
Vaccinex, Inc.
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
APOLLOMICS（冠科美博）宣布启动C-MET抑制剂APL-101的II期全球多中心临床试验SPARTA
May 21, 2020 07:10 ET
|
Apollomics, Inc.
评估不分肿瘤类型的各种MET失调；聚焦MET 14号外显子跳跃突变的非小细胞肺癌及有MET扩增和融合的肿瘤，包括非小细胞肺癌，多形性胶质母细胞瘤及其他肿瘤 中国杭州市和美国福斯特市报道, May 21, 2020 (GLOBE NEWSWIRE) -- Apollomics,...
Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101
May 21, 2020 07:10 ET
|
Apollomics, Inc.
- Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with...
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
May 21, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 13, 2020 17:02 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...